Burden of disease and adaptation to life in patients with Crohn’s perianal fistula: a qualitative exploration

Table 1 Demographic details for participants taking part in the unstructured face to face interviews

Participant	Sex	Age	Duration of CD (years)	Duration of perianal fistula (years)	Previous fistula surgery (excluding abscess drainage)	Current Stoma	Medication for fistula
1	Male	26	13	4	Yes	Yes	Nil
2	Female	26	4	1	Yes	No	Antibiotics – cyclical
3	Female	34	14	5	Yes	Yes	Nil
4	Male	23	5	3	Yes	No	Anti-TNF
5	Male	23	2	2	Yes	No	Nil
6	Female	16	2	0.5	no	No	Nil
7	Female	39	5	5	Yes	No	Anti-TNF
8	Female	52	9	7	Yes	No	Anti-TNF
9	Female	37	6	2	Yes	No	AZT
10	Female	35	15	1	Yes	No	Anti-TNF + AZT
11	Female	43	19	14	Yes	No	Anti-TNF + AZT
12	Female	20	3	3	Yes	No	Anti-TNF + AZT

AZT Azathioprine, anti-TNF – biologic medication, specifically anti-TNF alpha drugs (infliximab / adalimumab), nil none

ISSN: 1477-7525